S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Wall Street adds more to its big January after strong week
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Wall Street adds more to its big January after strong week
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Wall Street adds more to its big January after strong week
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Closing prices for crude oil, gold and other commodities
Is This The End of Capitalism? (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Wall Street adds more to its big January after strong week
NASDAQ:CLLS

Cellectis - CLLS Stock Forecast, Price & News

$3.10
-0.04 (-1.27%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.03
▼
$3.14
50-Day Range
$1.85
▼
$3.84
52-Week Range
$1.83
▼
$6.74
Volume
97,362 shs
Average Volume
141,953 shs
Market Capitalization
$141.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.20

Cellectis MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
216.1% Upside
$9.80 Price Target
Short Interest
Healthy
0.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.14mentions of Cellectis in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.67) to ($1.08) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

658th out of 1,055 stocks

Biological Products, Except Diagnostic Industry

104th out of 170 stocks

See Top Rated MarketRank™ Stocks Here

CLLS stock logo

About Cellectis (NASDAQ:CLLS) Stock

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Receive CLLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter.

CLLS Stock News Headlines

January 20, 2023 | finance.yahoo.com
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
January 20, 2023 | americanbankingnews.com
Cellectis (NASDAQ:CLLS) Price Target Cut to $6.00 by Analysts at JMP Securities
January 28, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
January 17, 2023 | finance.yahoo.com
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
December 29, 2022 | finance.yahoo.com
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
December 22, 2022 | finance.yahoo.com
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
December 1, 2022 | finance.yahoo.com
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
November 10, 2022 | finance.yahoo.com
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
January 28, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
November 10, 2022 | finance.yahoo.com
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
November 4, 2022 | finance.yahoo.com
Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022
October 14, 2022 | businesswire.com
Worldwide Repeat Expansion Disorders Treatment Industry to 2030 - North America Remains as the Global Leader and APAC to Present the Largest Opportunity - ResearchAndMarkets.com - Business Wire
October 12, 2022 | finance.yahoo.com
Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022 - Yahoo Finance
October 11, 2022 | globenewswire.com
Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022 - GlobeNewswire
October 11, 2022 | finance.yahoo.com
Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022
October 11, 2022 | nasdaq.com
Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study - Nasdaq
October 10, 2022 | globenewswire.com
Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy - GlobeNewswire
October 10, 2022 | finance.yahoo.com
Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy - Yahoo Finance
October 5, 2022 | globenewswire.com
Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting - GlobeNewswire
October 5, 2022 | finance.yahoo.com
Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
October 5, 2022 | nasdaq.com
Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy - Nasdaq
October 4, 2022 | streetinsider.com
Form 424B5 Calyxt, Inc. - StreetInsider.com
September 28, 2022 | globenewswire.com
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief - GlobeNewswire
September 28, 2022 | finance.yahoo.com
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
September 23, 2022 | uk.investing.com
Why T2 Biosystems Is Trading Higher By 18%; Here Are 28 Stocks Moving Premarket By Benzinga - Investing.com UK
September 23, 2022 | streetinsider.com
Form 6-K Cellectis S.A. For: Sep 22 - StreetInsider.com
September 21, 2022 | businesswire.com
Worldwide CAR T-Cell Therapy Industry to 2028 - Featuring Bluebird Bio, Intellia Therapeutics and Novartis International Among Others - ResearchAndMarkets.com - Business Wire
See More Headlines
Receive CLLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter.

CLLS Company Calendar

Last Earnings
11/03/2022
Today
1/28/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLLS
CUSIP
N/A
CIK
1627281
Web
www.cellectis.com
Phone
(318) 169-1600
Fax
33-1-81-69-16-06
Employees
294
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.80
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+293.5%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.30)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-114,200,000.00
Net Margins
-470.32%
Pretax Margin
-511.95%
Return on Equity
-54.50%
Return on Assets
-31.38%

Debt

Debt-to-Equity Ratio
0.10
Current Ratio
2.65
Quick Ratio
2.65

Sales & Book Value

Annual Sales
$67.07 million
Price / Sales
2.11
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.20 per share
Price / Book
0.60

Miscellaneous

Outstanding Shares
45,580,000
Free Float
38,099,000
Market Cap
$141.30 million
Optionable
Optionable
Beta
1.95

Key Executives

  • Dr. Andre Choulika Ph.D. (Age 58)
    Co-Founder, CEO & Director
    Comp: $879.06k
  • Dr. David J. D. Sourdive Ph.D. (Age 56)
    Director, Deputy CEO, Exec. VP of CMC and Manufacturing
    Comp: $580.28k
  • Dr. Bing C. Wang M.B.A. (Age 46)
    Ph.D., Chief Financial Officer
  • Valerie Cros
    Principal Financial Officer & Principal Accounting Officer
  • Mr. Jean Charles Epinat
    Chief Technological Officer
  • Dr. Philippe Duchateau Ph.D. (Age 60)
    Chief Scientific Officer
  • Mr. Stephan Reynier M.Sc. (Age 54)
    MSc, Chief Regulatory & Pharmaceutical Compliance Officer
  • Ms. Marie-Bleuenn Terrier (Age 41)
    Gen. Counsel & Sec. of the Board of Directors
  • Pascalyne Wilson
    Director of Communications
  • Ms. Kyung Nam-Wortman (Age 53)
    Exec. VP & Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













CLLS Stock - Frequently Asked Questions

Should I buy or sell Cellectis stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CLLS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLLS, but not buy additional shares or sell existing shares.
View CLLS analyst ratings or view top-rated stocks.

What is Cellectis' stock price forecast for 2023?

3 brokers have issued 1-year price objectives for Cellectis' stock. Their CLLS share price forecasts range from $2.00 to $24.00. On average, they anticipate the company's share price to reach $9.80 in the next twelve months. This suggests a possible upside of 216.1% from the stock's current price.
View analysts price targets for CLLS or view top-rated stocks among Wall Street analysts.

How have CLLS shares performed in 2023?

Cellectis' stock was trading at $2.10 on January 1st, 2023. Since then, CLLS shares have increased by 47.6% and is now trading at $3.10.
View the best growth stocks for 2023 here.

Are investors shorting Cellectis?

Cellectis saw a increase in short interest in January. As of January 15th, there was short interest totaling 277,600 shares, an increase of 31.0% from the December 31st total of 211,900 shares. Based on an average daily volume of 117,100 shares, the short-interest ratio is presently 2.4 days. Currently, 0.6% of the shares of the stock are sold short.
View Cellectis' Short Interest.

When is Cellectis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our CLLS earnings forecast.

How were Cellectis' earnings last quarter?

Cellectis S.A. (NASDAQ:CLLS) issued its quarterly earnings data on Thursday, November, 3rd. The biotechnology company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.05. The biotechnology company had revenue of $1.92 million for the quarter, compared to the consensus estimate of $22.45 million. Cellectis had a negative net margin of 470.32% and a negative trailing twelve-month return on equity of 54.50%.

What is André Choulika's approval rating as Cellectis' CEO?

13 employees have rated Cellectis Chief Executive Officer André Choulika on Glassdoor.com. André Choulika has an approval rating of 100% among the company's employees. This puts André Choulika in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 39.0% of employees surveyed would recommend working at Cellectis to a friend.

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC) and Sorrento Therapeutics (SRNE).

When did Cellectis IPO?

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Who are Cellectis' major shareholders?

Cellectis' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (1.32%).

How do I buy shares of Cellectis?

Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $3.10.

How much money does Cellectis make?

Cellectis (NASDAQ:CLLS) has a market capitalization of $141.29 million and generates $67.07 million in revenue each year. The biotechnology company earns $-114,200,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis.

How many employees does Cellectis have?

The company employs 294 workers across the globe.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The official website for the company is www.cellectis.com. The biotechnology company can be reached via phone at (318) 169-1600, via email at investors@cellectis.com, or via fax at 33-1-81-69-16-06.

This page (NASDAQ:CLLS) was last updated on 1/28/2023 by MarketBeat.com Staff